Stuart L. Goldberg, MD
The treatment landscape of acute myeloid leukemia (AML) has undergone a significant transformation in the past year with the introduction of many novel agents, says Stuart L. Goldberg, MD.
on Hematologic Malignancies, Stuart, a hematologist in the Division of Leukemia at John Theurer Cancer Center, and chief scientific officer of Cota, discussed the management of patients with AML as well as those with MDS.
OncLive®: Please provide an overview of your presentation.
: Prior to 2017, the management and evaluation of patients with AML was relatively simple. We would decide whether the patient was fit or unfit for therapy, and if they were fit, we would offer them standard induction chemotherapy. We have done that for 40 years. The management of AML has changed dramatically in the past year with the approval of several new agents. AML is no longer a simple disease; it is complex, and the evaluation needs to be done properly so that we can select the right patient for the right therapy.
Can you speak to how these new approvals have impacted the field?
This has truly been a banner year with the FDA approval of 4 new agents. Also, we have seen the use of other approved agents in AML that are showing efficacy in the elderly population. The field has become fairly complex; you need to do a very good workup because each of our agents are geared toward a specific subtype.
... to read the full story